Beispiel: Heart Attack

Suchen Sie in klinischen Studien nach: Topotecan

Insgesamt 385 ergebnisse

NCT02303028

Aktiv, nicht rekrutierend

Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid Tumours

Bedingungen: Solid Tumors
NCT04156347

Noch nicht rekrutiert

Episcleral Topotecan for Treatment of Group D Retinoblastoma

Bedingungen: Retinoblastoma
NCT04213937

Rekrutierung

Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer

Bedingungen: Extensive Stage Small Cell Lung Cancer
NCT02963090

Aktiv, nicht rekrutierend

Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer

Bedingungen: Small Cell Lung Cancer
NCT02649673

Aktiv, nicht rekrutierend

LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

Bedingungen: Small Cell Lung Cancer; Ovarian Cancer
NCT02500459

Beendet

Topotecan in Glioma Undergoing A Clinically-Indicated Surgical Resection

Bedingungen: Brain Tumor; High Grade Glioma
NCT04428879

Rekrutierung

Topotecan Episcleral Plaque for Treatment of Retinoblastoma

Bedingungen: Retinoblastoma
NCT01736800

Zurückgezogen

Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors

Bedingungen: Central Nervous System (CNS) Metastases; Brain Metastases
NCT01037023

Abgeschlossen

Regulatory Hycamtin(Oral) PMS

Bedingungen: Lung Cancer, Small Cell
NCT00257816

Abgeschlossen

Weekly IV Topotecan and Cisplatin With Radiation in Cervical Carcinoma

Bedingungen: Cervical Cancer
NCT00294190

Abgeschlossen

Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer

Bedingungen: Small Cell Lung Cancer; Carcinoma, Small Cell
NCT03927274

Rekrutierung

Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma

Bedingungen: Glioma of Brain
NCT00610571

Abgeschlossen

Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas

Bedingungen: Glioblastoma; Gliosarcoma; Anaplastic Astrocytoma
NCT01630018

Abgeschlossen

Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial

Bedingungen: Epithelial Ovarian Cancer
NCT00158886

Beendet

Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer

Bedingungen: Carcinoma, Renal Cell
NCT01600573

Unbekannter Status

Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)

Bedingungen: Ovarian Cancer
NCT00611468

Abgeschlossen

Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors

Bedingungen: Metastatic Solid Tumor
NCT01497873

Abgeschlossen

A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer

Bedingungen: Small Cell Lung Cancer
NCT02348398

Zurückgezogen

Phase II Study of Pazopanib and Topotecan in Cervical Cancer

Bedingungen: Cervical Cancer
NCT03896503

Rekrutierung

Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

Bedingungen: Bladder Small Cell Carcinoma; Extensive Stage Lung Small Cell Carcinoma; Extrapulmonary Small Cell Carcinoma; Limited Stage Lung Small Cell Carcinoma; Platinum-Resistant Lung Small Cell Carcinoma; Platinum-Sensitive Lung Small Cell Carcinoma; Prostate Small Cell Carcinoma; Recurrent Lung Small Cell Carcinoma
NCT01003938

Beendet

Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer

Bedingungen: Ovarian Cancer
NCT00918320

Abgeschlossen

Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours

Bedingungen: Neuroblastoma; Brain Tumors; Solid Tumors
NCT00437307

Abgeschlossen

Hycamtin Plus Carboplatin Versus Established Regimens for the Treatment of Ovarian Cancer Relapse

Bedingungen: Ovarian Cancer
NCT00308165

Unbekannter Status

Safety Study of Intracerebral Topotecan for Recurrent Brain Tumors

Bedingungen: Brain Neoplasms, Primary Malignant
NCT03227016

Rekrutierung

Study in Patients With SCLC of Veliparib in Combination With Topotecan

Bedingungen: Small Cell Lung Cancer SCLC